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Pirh2, a p53-Induced Ubiquitin-Protein Ligase,
Promotes p53 Degradation
stress or DNA damage are given time to repair the dam-
age or are eliminated from the population (Levine, 1997;
Vogelstein et al., 2000). p53 protein is positively regu-
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cations including phosphorylation and acetylation (Ap-1Ontario Cancer Institute and Department of
Medical Biophysics pella and Anderson, 2001). In its inactive form, p53 is
bound to Mdm2 protein. Binding to Mdm2 inhibits theUniversity of Toronto
610 University Avenue transcriptional activity of p53 (Momand et al., 1992;
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Ontario by the 26S proteasome (Haupt et al., 1997; Kubbutat et
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Toronto p53-inducible gene. This dependency creates an auto-
regulatory feedback loop in which both the activity ofOntario
Canada M5G 1X8 p53 protein and the expression of Mdm2 are regulated
(Barak et al., 1993; Wu et al., 1993). Stress-induced3 Advanced Medical Discovery Institute
University Health Network phosphorylation of two critical residues on p53, Ser15
and Ser20, results in Mdm2 dissociation and stabiliza-620 University Avenue
Toronto tion of p53 (Vousden, 2002). Subsequent phosphoryla-
tion and acetylation leads to activation of the sequence-Ontario
Canada M5G 2C1 specific DNA binding and transcriptional activities of
p53 (Appella and Anderson, 2001; Prives and Manley,4 Department of Molecular Genetics
The University of Texas 2001). The physiological significance of the p53:Mdm2
interaction was dramatically illustrated by the findingM.D. Anderson Cancer Center
Houston, Texas 77030 that deletion of Mdm2 in the mouse resulted in embry-
onic lethality, and that simultaneous loss of p53 com-
pletely rescued this phenotype (Montes de Oca Luna et
al., 1995; Jones et al., 1995). JNK has also been shownSummary
to bind to the central domain of p53 (residues 97–155)
in nonstressed cells and to promote ubiquitination andThe p53 tumor suppressor exerts anti-proliferative ef-
fects in response to various types of stress including degradation of p53 independently of Mdm2 (Adler et al.,
1997; Fuchs et al., 1998). Experiments performed in JNK-DNA damage and abnormal proliferative signals. Tight
regulation of p53 is essential for maintaining normal depleted, Mdm2 null extracts in which p53 ubiquitination
was reduced but not abolished, suggested the existencecell growth and this occurs primarily through post-
translational modifications of p53. Here, we describe of other molecules capable of targeting p53 for ubiquiti-
nation (Fuchs et al., 1998).Pirh2, a gene regulated by p53 that encodes a RING-
H2 domain-containing protein with intrinsic ubiquitin- Here, we describe a gene regulated by p53 that en-
codes a predicted protein of 261 amino acids, which weprotein ligase activity. Pirh2 physically interacts with
p53 and promotes ubiquitination of p53 independently have named Pirh2. We present evidence that Pirh2 can
directly bind p53 protein both in vitro and in vivo, andof Mdm2. Expression of Pirh2 decreases the level of
p53 protein and abrogation of endogenous Pirh2 ex- that it can repress p53-dependent transactivation and
growth suppression. Pirh2 contains a RING-H2 domainpression increases the level of p53. Furthermore, Pirh2
represses p53 functions including p53-dependent and has intrinsic E3 ubiquitin ligase activity. We show
that Pirh2 regulates the steady-state level of p53 proteintransactivation and growth inhibition. We propose that
Pirh2 is involved in the negative regulation of p53 func- and that it promotes ubiquitination of p53 independently
of Mdm2. Hence, Pirh2, like Mdm2, participates in antion through physical interaction and ubiquitin-medi-
ated proteolysis. Hence, Pirh2, like Mdm2, participates autoregulatory feedback loop that serves to control p53




Identification of Pirh2, a p53-Inducible Gene
The ability of p53 protein to inhibit cell cycling or pro- that Encodes a RING-H2 Protein
mote apoptosis is closely associated with its tumor sup- To identify p53-target genes, we used the method of
pressor function. In this way, cells that are growing inap- differential display and a mouse cell line containing a
propriately or that have been subjected to deleterious temperature-sensitive p53 allele, DP16.1/p53ts (John-
son et al., 1993). We detected a 1.7 kb transcript that
was reproducibly more abundant in DP16.1/p53ts cells*Correspondence: benchimo@uhnres.utoronto.ca
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Figure 1. p53 Activates Pirh2 Expression
(A) Northern blot in which polyA RNA from multiple mouse tissues (Clontech) was hybridized with a mouse Pirh2 cDNA probe. Two Pirh2
transcripts of approximately 1.6- and 1.7 kb were detected. Actin expression was examined as a loading control.
(B) RNA was isolated from parental DP16.1 cells and DP16.1/p53ts cells after incubation at 32C for the times indicated. RNA (10 g) was
run in each lane and hybridized to Pirh2, Mdm2, p21WAF1, and GAPDH cDNA probes. RNA was visualized by autoradiography. The relative
abundance of Pirh2 mRNA was determined by phosphorimage analysis after normalizing to the level of GAPDH mRNA in each sample.
(C) Northern blot analysis of RNA isolated from wild-type (p53/) and p53/ early passage MEFs before and after -irradiation with a dose
of 6 Gy at the times indicated. The blot was hybridized with the indicated cDNA probes and analyzed as in (B).
(D–E) Northern blot analysis of RNA isolated from mouse BaF3 and BaF3/DD cells, and from human BJT and BJT/DD cells treated with
cisplatin for the times indicated. The blot was hybridized with the indicated cDNA probes and analyzed as in (B).
cultured at 32C compared with parental DP16.1 cells cells in response to p53 activation at 32C by Northern
blot analysis (Figure 1B). Pirh2 mRNA levels increasedgrown at 32C and DP16.1/p53ts cells grown at 37C.
Using the differential display fragment representing this within 4 hr of p53 activation and reached their highest
levels at 16 hr (4.2-fold). The amount of Pirh2 mRNAtranscript and 5RACE, and a combination of database
searching and RT-PCR analyses, we obtained a cDNA was unchanged in DP16.1 cells at 32C, indicating that
Pirh2 mRNA induction in DP16.1/p53ts cells is depen-clone with an insert of 1226 bp. This sequence includes
an open reading frame that encodes a 261 amino acid dent on p53 and not simply the result of a change in
temperature. In comparison, Mdm2 and p21WAF1 induc-protein with a predicted molecular mass of 30 kDa (see
Supplemental Figure S1 available at http://www.cell. tion in DP16.1/p53ts cells was strongest at 8 hr (2.6-
fold and 9.3-fold, respectively).com/cgi/content/full/112/6/779/DC1). The predicted
protein contains a cysteine-rich RING motif defined by RNA samples from various cell lines were examined by
Northern blotting to investigate the relationship betweenthe consensus sequence CXXCX(9,39)CX(1,3)HX(2,3)C/
HXXCX(4,48)CXXC with eight cysteines and histidines p53 and Pirh2 expression. Pirh2 mRNA was induced in
response to -irradiation in wild-type MEFs (2.4-fold)that coordinate two zinc ions (Borden, 2000). We have
named this protein Pirh2 (for p53-induced protein with but not in p53/ MEFs (Figure 1C). We also observed
induction of Pirh2 mRNA in response to cisplatin treat-a RING-H2 domain).
Northern blot analysis of RNA from various adult ment in the wild-type p53-expressing, murine pro B cell
line, BaF3 (2.1-fold), but not in BaF3/DD cells, an iso-mouse tissues identified two Pirh2 mRNA transcripts
with approximate lengths of 1.7 kb and 1.6 kb (Figure genic derivative expressing the C-terminal fragment of
p53 (Figure 1D). This fragment has been shown to act1A). Pirh2 mRNA expression was highest in the liver;
relatively high levels were expressed in testis and heart, as a potent trans-dominant repressor of wild-type p53
through its ability to prevent the formation of functionaland lower levels were expressed in muscle and spleen.
To confirm that Pirh2 is a p53-regulated gene, we p53 tetramers (Shaulian et al., 1992). In addition, we
saw an increase in Pirh2 expression in cisplatin-treatedstudied the kinetics of Pirh2 induction in DP16.1/p53ts
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Figure 2. The p53-Consensus Binding Sequence in Pirh2 is Responsive to p53
(A) The potential p53 binding site in intron 3 of the mouse Pirh2 gene is indicated above the p53 consensus binding site (El-Deiry et al., 1992),
with R denoting purine, Y denoting pyrimidine, and W denoting A or T. The numbering is relative to the first nucleotide of the proposed ATG
initiator methionine. The four exons shown cover only the first 135 amino acids of the Pirh2 open reading frame. The potential p53 binding
site in Pirh2 matches the consensus at 19 out of 20 nucleotides.
(B) Electrophoretic mobility shift assays were performed with purified truncated p53 (residues 82–360). Binding reactions were performed with
a 32P-labeled double-stranded oligonucleotide containing the p53 consensus binding sequence in Pirh2 or with an unrelated C oligonucleotide
having the same nucleotide composition. Unlabeled cold competitor (double-stranded Pirh2 or unrelated C oligonucleotide) was added at
10-fold, 50-fold, and 100-fold molar excess over the labeled Pirh2 oligonucleotide.
(C) Chromatin immunoprecipitation assay of p53 DNA binding activity in p53-expressing DP16.1/p53ts cells and parental p53 null DP16.1
cells. DP16.1/p53ts cells were cultured at 32C and harvested 8 hr later. A rabbit polyclonal antibody to p53 (FL-393) or control rabbit IgG
was used. PCR analysis (using primers to intron 3 of Pirh2 or Pirh2 promoter or intron 1 of Mdm2) is shown using input DNA (1/20 of ChIP)
or DNA after ChIP. Amplification products ranged in length from 200 bp to 240 bp.
(D) Histogram representing the ability of wild-type p53 or the p53V143A mutant to transactivate a luciferase reporter bearing the p53 binding
sequence from Pirh2 (Pirh2-Luc) or an unrelated control sequence (C-Luc). A -galactosidase reporter construct was included in all the
transfection mixes and used for normalization. Error bars indicate SEM (n  8).
human BJT fibroblasts (2.5-fold) but not in the isogenic ing site at 19 out of 20 base pairs and contained an 8
bp spacer between the two half-sites. Electrophoreticderivative, BJT/DD, expressing the dominant-negative
C-terminal fragment of p53 (Figure 1E). We also ob- mobility shift experiments indicated that p53 bound the
Pirh2 element but not an unrelated control sequenceserved induction of Pirh2 mRNA in response to -irradia-
tion and UV-irradiation in mouse ES cells (data not (Figure 2B). We also tested the binding of p53 to the
Pirh2 intron 3 site using chromatin immunoprecipitationshown). We did not detect any increase in the level
of Pirh2 mRNA after -irradiation in two wild-type p53 (ChIP). DP16.1/p53ts cells were grown at 32C for 8 hr
and subjected to ChIP analysis by immunoprecipitationexpressing cell lines that we tested (MCF-7 and OCI/
AML-4) (data not shown). Moreover, we did not detect with control IgG or p53-specific polyclonal antibody (FL-
393), followed by PCR analysis of the of the Pirh2 intronany increase in the level of Pirh2 in UV-irradiated MEFs
or in UV- or -irradiated BJT cells. Hence, the induction 3 region surrounding the p53 response element. Amplifi-
cation of the Pirh2 promoter (Pirh2-Pr) and of a regionof Pirh2 mRNA by p53 appears to be dependent on cell
type and the DNA damaging agent used to activate p53. containing a p53 binding site in the first intron of the
Mdm2 gene (Juven et al., 1993; Wu et al., 1993) served
as negative and positive controls, respectively. The dataIntron 3 of Pirh2 Contains a p53 Binding Site
Isolation and examination of mouse genomic sequences presented in Figure 2C show that Pirh2 intron 3 was
bound by p53 in vivo.covering the first four exons of Pirh2, including 8.6 kbp
upstream of the first exon, revealed the presence of a To determine whether p53 activates transcription of a
minimal promoter containing the p53 binding sequenceputative p53 binding site within the third intron of Pirh2
(Figure 2A). This site matched the consensus p53 bind- present in intron 3 of Pirh2, a double-stranded oligonu-
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cleotide containing one copy of this element was in- GST-Pirh2 but not to GST alone (Figure 3E). Finally, we
wished to determine if endogenous p53 and Pirh2 couldserted into the luciferase reporter vector pGL3E1bTATA
(designated Pirh2-Luc). Human Saos2 osteosarcoma interact under more physiological conditions in the ab-
sence of ectopic overexpression. An IP/Western blottingcells, which harbor a homozygous deletion of the p53
locus and do not produce p53 protein, were transfected experiment was performed using extracts prepared from
human BJT fibroblasts. We observed that p53 coimmu-with Pirh2-Luc along with plasmids expressing either
wild-type p53 or mutant p53 (p53 V143A). Wild-type p53 noprecipitated with Pirh2. In the reciprocal experiment
using PAb1801 antibodies to immunoprecipitate p53,enhanced luciferase expression from Pirh2-Luc moder-
ately, 3.7-fold. p53 V143A had no activity in these assays we observed that Pirh2 coimmunoprecipitated with p53
(Figure 3F). We conclude that p53 and Pirh2 physically(Figure 2D). In comparison, we found that luciferase
expression from reporter plasmids containing the p53 interact in vivo.
binding site from p21WAF1 or from Mdm2 were stimulated
57-fold and 11-fold, respectively, by p53 (data not Residues 120 to 137 of Pirh2 Are Required
shown). Collectively, these data indicate that the DNA for Binding to p53
sequence within intron 3 of mouse Pirh2 (between bases To identify the region of Pirh2 that interacts with p53, a
5880 and 5907) constitutes a bona fide p53 binding site. series of Pirh2 deletion mutants was expressed in bacte-
ria as GST-fusion proteins (Figure 4A, top image). These
were employed in a GST-pull-down assay with 35S-Physical Interaction of Pirh2 with p53
labeled in vitro translated p53 protein (Figure 4A, bottomPolyclonal antibodies against bacterially expressed hu-
image, left). All of the Pirh2 fragments, with the exceptionman and mouse Pirh2 proteins were produced in rabbits
of an N-terminal fragment containing the first 60 amino(see Supplemental Figure S2 available at http://www.
acids, were capable of binding to p53. The data, summa-cell.com/cgi/content/full/112/6/779/DC1). Using these an-
rized in Figure 4B, indicate that a region of Pirh2 encom-tibodies for Western blotting, we detected an increase
passing residues 120 to 137 is required for binding p53.in the level of Pirh2 protein in DP16.1/p53ts cells but
To confirm this finding, a GST-Pirh2 fusion protein lack-not parental DP16.1 cells when these cells were shifted
ing residues 120–137 was expressed and used in a GSTto 32C to activate p53 (Figure 3A). We also detected
pull-down assay. This deletion mutant was unable toincreased expression of Pirh2 protein in irradiated MEFs
bind p53 (Figure 4A, middle image). To investigateas well as in cisplatin-treated BaF3 and BJT cells (Figure
whether the binding between p53 and Pirh2 is direct or3B) consistent with the RNA data shown in Figure 1.
indirect, purified GST-Pirh2 was mixed with purified His-In each of these experimental models, increased Pirh2
tagged p53. Protein complexes were collected with glu-expression was dependent on p53.
tathione-agarose beads and the presence of bound p53Plasmids expressing Pirh2 and p53 were cotrans-
assessed by immunoblotting with anti-His antibody (Fig-fected into Saos2 cells. The transfected cells were la-
ure 4A, right image). p53 bound to full-length GST-Pirh2beled with [35S]methionine/cysteine and protein extracts
but not to GST-Pirh2 	120–137 or to GST. We concludewere subjected to immunoprecipitation with the Pirh2
that p53 binds directly to Pirh2.antibody. Radiolabeled Pirh2 protein was detected in
cells transfected with the Pirh2 cDNA plasmid and not
The Central Region of p53 (Residues 82–292)in cells transfected with the empty pcDNA3 vector.
Binds Pirh2Coimmunoprecipitation of a 53 kDa protein was seen
To identify the region of p53 required for the associationonly in cells cotransfected with Pirh2 and p53 expres-
with Pirh2, we performed pull-down assays with in vitrosion plasmids (Figure 3C). To confirm that the 53 kDa
translated 35S-labeled Pirh2 and a series of bacteriallyprotein was p53, we performed an IP/Western blotting
expressed p53 deletion mutants tagged with GST or Hisexperiment using extracts prepared from Saos2 cells
(Figure 4C, top image). The region of p53 extendingthat had been transiently transfected with plasmids ex-
from residues 82 to 292 exhibited binding to Pirh2, whilepressing p53, Pirh2, and various Pirh2 mutants that dis-
neither a p53 fragment containing only the N-terminalrupt the RING domain. Extracts were mixed with the
portion, nor a p53 fragment containing only the C-ter-Pirh2 antibody and the resulting immune complexes
minal portion was capable of binding Pirh2 (Figure 4C,were collected and analyzed by immunoblotting with
bottom).the p53-specific monoclonal antibody PAb1801 (Figure
3D, top image) or with antibodies to Pirh2 (Figure 3D,
bottom image). p53 coimmunoprecipitated with Pirh2. Pirh2 Expression Reduces the Amount
of Endogenous p53 ProteinBinding between these molecules appeared not to be
dependent on the RING-H2 domain of Pirh2. Next, Saos2 We tested the ability of Pirh2 to regulate the level of
endogenous wild-type p53 protein in MCF-7 cells. Tran-cells were cotransfected with plasmids expressing His-
tagged Pirh2 and p53, and the extracts were immuno- sient overexpression of Pirh2 resulted in a reduction in
the level of p53 (Figure 5A). In addition, we testedprecipitated with a monoclonal antibody against His.
p53 protein was detected in the anti-His immunoprecipi- whether endogenous Pirh2 is critical in regulating the
level of p53 protein in BJT cells. An antisense oligonucle-tate confirming the in vivo interaction between p53 and
Pirh2 (Figure 3D). Next, we performed an in vitro GST otide directed against Pirh2 effectively inhibited Pirh2
expression in BJT cells while a control-scrambled oligo-pull-down assay. Cell extracts were prepared from
DP16.1 cells ectopically expressing mouse p53 and from nucleotide had no effect (Figure 5B). Importantly the
decrease in Pirh2 was accompanied by an increase inSaos2 cells ectopically expressing human p53. p53 pro-
tein present in these extracts bound to immobilized the level of endogenous p53 protein (Figure 5B). Next,
Negative Control of p53 by Pirh2
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Figure 3. Interaction between p53 and Pirh2
(A) DP16.1/p53ts and DP16.1 cells were cul-
tured at 37C or at 32C for the times indi-
cated. Immunoblot showing Pirh2 protein ac-
cumulation in response to p53 activation. An
antibody against -actin was used as a load-
ing control.
(B) Immunoblot showing Pirh2 protein levels
in -irradiated MEFs (p53/ and p53/), cis-
platin-treated BaF3 and BaF3/DD cells, and
cisplatin-treated BJT and BJT/DD cells.
(C) p53 null Saos2 cells were transfected with
the indicated expression plasmids in dupli-
cate; 24 hr later, the cells were metabolically
labeled with 35S-methionine/cysteine for 2 hr
and extracts were prepared. Pirh2 protein
was immunoprecipitated, the immune com-
plexes were collected with protein A Sepha-
rose beads, resolved by SDS-PAGE, and vis-
ualized by autoradiography.
(D) Saos2 cells were transfected with p53 and
Pirh2 expression plasmids as indicated.
Equal amounts of cell extract were immuno-
precipitated with the Pirh2 antibody (left) or
with an antibody directed against His (right)
and analyzed by immunoblotting following
SDS-PAGE with antibodies directed against
p53 (PAb1801) or against Pirh2.
(E) In vitro interaction of Pirh2 and p53 protein
evaluated in GST pull-down assays. The abil-
ity of mouse p53 (top) or human p53 protein
(bottom) present in cell extracts to be re-
tained by GST (lane 1) or GST-Pirh2 fusion
protein (lane 2) was analyzed by immunoblot-
ting following SDS-PAGE. A total of 1 g GST
and 1 g GST-Pirh2 were applied to glutathi-
one beads. p53 was visualized by immu-
noblot analysis of the glutathione-agarose
complexes using antibodies to mouse
(PAb421) or human (PAb1801) p53. Input (50
g of extract) represents 1/6 of that used for
GST pull-down.
(F) Cell extracts were prepared using human
BJT fibroblasts. Equal amounts of extract
were immunoprecipitated with the indicated
antibodies and analyzed by immunoblotting
with antibodies to detect p53 (PAb1801) or
Pirh2.
we generated a series of MCF-7 clones that stably ex- cells. Cell extracts were subjected to immunoblotting
with antibodies to Pirh2, Mdm2, or HA. Mdm2 and Pirh2press hPirh2, Mdm2, or various hPirh2 mutants: 	RING
(containing an internal deletion of the RING-H2 domain were expressed in the transfected cells (Figure 6A) and
caused a large increase in protein ubiquitination thatthat removes residues 145 to 186), and C164A and
H169A (in which the metal coordinating residues Cys164 was not seen in the absence of co-expressed HA-tagged
ubiquitin (Figure 6A, compare lanes 7 and 8 with lanesand His169 within the RING-H2 domain are replaced
with Ala). The immunoblot shown in Figure 5C indicates 3 and 4).
To determine if Pirh2 can promote ubiquitination oflower levels of endogenous p53 protein in clones ex-
pressing Pirh2 or Mdm2 in comparison with clones ex- p53 in vivo, p53 and HA-tagged ubiquitin were co-
expressed in Saos2 cells together with Pirh2 or Mdm2.pressing Pirh2 RING mutants or with clones containing
the empty vector. p53 mRNA levels were not affected Ectopically expressed p53 appeared as a doublet in
these experiments; the smaller species may be the resultby ectopic expression of Pirh2 (data not shown) indicat-
ing that p53 protein is the target of Pirh2. Together, of degradation or internal initiation. Importantly the over-
all level of p53 was lower when p53 was co-expressedthese data indicate that Pirh2, like Mdm2, can regulate
the steady-state level of p53 protein. with Pirh2 or Mdm2 (Figure 6A, lanes 2, 6, 9, and 10;
Figure 6B, lanes 3–5) consistent with our previous re-
sults. We observed a massive increase in the amountPirh2 Has Ubiquitin-Protein Ligase Activity
To determine if Pirh2, like Mdm2, can mediate protein of protein ubiquitination when p53 was co-expressed
with Mdm2 or with Pirh2 (Figure 6A, lanes 9 and 10).ubiquitination in vivo, vectors expressing Pirh2, Mdm2,
and HA-tagged ubiquitin were transfected into Saos2 This level of ubiquitination was not seen with p53 alone
Cell
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Figure 4. Mapping the Interaction Sites on Pirh2 and p53
(A) The region of Pirh2 involved in binding to p53 was analyzed in GST pull-down assays. GST-Pirh2 fusion proteins were affinity purified and
analyzed by SDS-PAGE and Coomassie blue staining (top). The ability of the various truncated Pirh2 fusion proteins to bind to in vitro translated
35S-labeled p53 protein (left image) or to unlabeled in vitro translated p53 protein (middle image) or to purified His-p53 fusion protein (right
image) was analyzed by SDS-PAGE and autoradiography (left bottom image) or by immunoblotting with PAb1801 antibodies against p53
(middle bottom image) or by immunoblotting with antibodies against His (right bottom image), respectively. The right lane in the right image
represents the input His-p53 protein used in the binding reaction.
(B) Schematic representation of Pirh2 truncations fused to GST. The binding site for p53, based on the data provided in (A), is indicated.
(C) The region of p53 involved in binding to Pirh2 was analyzed in pull-down assays. GST-p53 or His-p53 fusion proteins were affinity purified
and analyzed by SDS-PAGE and Coomassie blue staining (top). The ability of the various p53 fusion proteins to bind to in vitro translated 35S-
labeled Pirh2 was analyzed by SDS-PAGE and autoradiography (bottom).
(Figure 6A, lane 6). In parallel experiments, p53 was p53 protein was lower when p53 was co-expressed with
Pirh2 or with Mdm2. In the IP/Western blot shown inimmunoprecipitated with PAb1801 antibodies and ana-
lyzed by immunoblotting with HA antibodies to detect Figure 6D, immunoprecipitated p53 was heavily ubiquiti-
nated in the presence of Pirh2 or Mdm2. These resultsubiquitinated p53 (Figure 6B, top image) or with Ab-7
to detect all the p53 (Figure 6B, bottom image). p53 (or provide evidence that Pirh2 functions independently of
Mdm2. Next, we performed pulse-chase experiments toproteins that coimmunoprecipitate with p53) appeared
heavily ubiquitinated in the presence of Mdm2 and to a investigate the role of Pirh2 in regulating the stability
of p53 protein. p53/ Mdm2/ double-null cells werelesser extent in the presence of Pirh2 (Figure 6B, top
image). The p53 immunoblot (Figure 6B, bottom image) transfected with a p53 expression vector in the presence
or absence of Pirh2, pulse labeled with 35S-methionine/revealed the presence of high molecular weight species
of p53 generated in the presence of Mdm2 or Pirh2 that cysteine and chased in non-radioactive medium. p53
protein was immunoprecipitated, separated by gel elec-are consistent with ubiquitination. The distribution of
p53-related species observed on the blot suggests that trophoresis and visualized by autoradiography. Ectopi-
cally expressed p53 has a half-life of about 240 min inPirh2 may be more proficient at polyubiquitination than
Mdm2. Mdm2 null MEFs. In the presence of Pirh2, the p53 half-
life decreased to about 80 min (Figure 6E). These dataThese experiments were performed in Mdm2-positve
cells and, as a result, they raised the question of whether indicate that Pirh2 regulates the stability of p53 in Mdm2
null cells.Pirh2 was promoting ubiquitination through Mdm2. To
investigate the possible relationship between Pirh2 and To determine if Pirh2 has intrinsic ubiquitin-protein
ligase activity, we used an in vitro ubiquitination assayMdm2, we compared the ubiquitination promoting activ-
ity of ectopically expressed Pirh2 and Mdm2 in p53/ (Lorick et al., 1999). Affinity purified GST-Pirh2 or GST
alone were added to bacterial extracts containing re-Mdm2/ double-null MEFs. As indicated in Figure 6C,
Pirh2 promoted protein ubiquitination in Mdm2 null cells. combinant E1 and E2 (UbcH5b), and His-tagged ubiqui-
tin. Pirh2-mediated ubiquitination was readily detectedThe extent of ubiquitination promoted by Pirh2 was simi-
lar to that promoted by Mdm2. Moreover, the level of and was dependent on the presence of E1 and E2 (Figure
Negative Control of p53 by Pirh2
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Figure 5. Pirh2 Interferes with the Steady-State Level of p53 Protein
(A) Wild-type p53 expressing MCF-7 cells were transfected with increasing amounts of the Pirh2 expression plasmid. The levels of ectopically
expressed Pirh2 protein and endogenous p53 protein were determined by immunoblotting with Pirh2 antibodies or PAb1801, respectively.
An antibody against -actin was used as a loading control.
(B) BJT cells were exposed to Pirh2 antisense oligonucleotide (AS) or to scrambled control oligonucleotide (C-oligo) for 48 hr. The levels of
endogenous Pirh2 and p53 proteins were determined by immunoblotting with Pirh2 antibodies or PAb1801, respectively. An antibody against
-actin was used as a loading control.
(C) MCF-7 clones stably transfected with vectors expressing hPirh2 (PIRH2-1, PIRH2-2), Pirh2-H169A, Pirh2-C164A, Pirh2 	RING (PIRH2-
	RING-3, PIRH2-	RING-7), Mdm2, or empty pcDNA3.1 vector (pcDNA3-1, pcDNA3-2) were subjected to immunoblotting using antibodies
that recognize p53 (PAb1801), Mdm2, Pirh2, or -actin. p53 null Saos2 cell extracts served as negative controls for p53 staining.
6F). To determine if p53 could serve as a substrate for erase activity was decreased in cells expressing Pirh2,
Pirh2	RING, and Mdm2 (Figure 7B). These data indicatePirh2-dependent ubiquitination in vitro, reactions (lack-
ing the bacterial extract) were supplemented with 35S- that Pirh2 represses p53-dependent transactivation and
that this repression does not require the RING domainlabeled in vitro translated p53 (Figure 6G) or with purified
GST-p53 fusion protein (Figure 6H). Ubiquitination of of Pirh2. These data suggest that Pirh2 impairs the trans-
activation function of p53 without targeting it for degra-35S-labeled p53 was evaluated by SDS-PAGE and auto-
radiography and ubiquitination of purified GST-p53 was dation.
evaluated by Western blotting. Higher molecular weight
species indicative of addition of ubiquitin moieties on Pirh2 Interferes with the Growth Inhibitory
p53 were seen only in the presence of added E1 and Activity of p53
E2 (Figures 6G and 6H). Next, we investigated the effect of Pirh2 on p53-depen-
dent growth suppression. We used a cotransfection
assay in which the pCMV-CD20 expression vector en-Pirh2 Interferes with the Transcriptional
Activity of p53 Protein coding the B cell surface marker CD20 was cotrans-
fected with or without p53 into p53-negative H1299 cells.To investigate the functional consequences of Pirh2 in-
teraction with p53, we tested the effect of Pirh2 expres- The number of CD20-positve cells was determined by
flow cytometry 48 hr after transfection and a decreasesion on p53-mediated transcriptional activation. Saos2
cells were cotransfected with a luciferase reporter con- in the number of CD20-positive cells provided a measure
of p53-mediated cell death. Expression of p53 alonestruct (p21-Luc) containing the p53 binding site from
the p21WAF1 promoter and p53, alone or in combination resulted in a reduction in cell viability and this was largely
prevented by co-expressed Pirh2 (Figure 7C). To deter-with Pirh2 or Mdm2. As shown in Figure 7A, Pirh2 and
Mdm2 both repressed p53-mediated transactivation. mine if this effect depended on Pirh2 E3 ligase activity,
we studied three Pirh2 mutants: Pirh2 	120–137 is de-Furthermore, a RING-less mutant of Pirh2 retained the
ability to repress p53-mediated transactivation. Next, fective in binding p53, and Pirh2 	RING (deletion of
residues 145–186) and Pirh2 1–137 are defective in p53we transfected the p21-Luc reporter into MCF-7 clones
that stably express Pirh2, Pirh2 	RING, or Mdm2. Lucif- degradation and E3 ligase activity (Figure 5 and data
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Figure 6. Pirh2 Promotes Ubiquitination and Serves as an E3 Ubiquitin Ligase
(A) Saos2 cells were transfected with vectors expressing HA-tagged ubiquitin (Ub), p53, Mdm2, and Pirh2 as indicated. Cell extracts were
prepared 48 hr later, resolved by SDS-PAGE and analyzed by immunoblotting with the indicated antibodies.
(B) Similar to (A) except that equal amounts of cell extracts were immunoprecipitated with PAb1801 antibody against p53 and analyzed by
immunoblotting with antibodies to HA (12CA5) (top) or p53 (Ab-7) (bottom).
(C) Similar to (A) except that p53/ Mdm2/ double-null MEFs were used as recipient cells for transfection using the indicated plasmids.
(D) Cell extracts were prepared following transfection of the p53/ Mdm2/ double-null MEFs with the indicated plasmids. Extracts were
immunoprecipitated with FL-393 antibody against p53 and analyzed by immunoblotting with antibodies to HA.
(E) Pulse-chase analysis of ectopically expressed p53 in the presence or absence of Pirh2 in p53/ Mdm2/ double-null MEFs. Cells were
metabolically labeled and chased for the indicated time points. p53 was immunoprecipitated with FL-393. The data shown in the inset were
quantitated by phosphorimage analysis. The dashed line represents p53 alone, and the solid line represent p53 in the presence of Pirh2.
(F) GST-Pirh2 was evaluated for E3 activity in the presence of recombinant E1, UbcH5b (E2), and His-tagged Ub as indicated. Following the
ubiquitination reaction, the samples were subjected to SDS-PAGE and immunoblotting with a His antibody to reveal ubiquitinated products.
(G) GST-Pirh2 was evaluated for its capacity to ubiquitinate 35S-labeled p53 translated in a reticulocyte lysate. Each reaction contained 35S-
labeled p53 in addition to the indicated ubiquitination components. After the in vitro ubiquitination reaction, the samples were analyzed by
SDS-PAGE and autoradiography.
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Figure 7. Pirh2 Interferes with the Transcriptional and Growth Suppressing Activities of p53
(A) Transcriptional activity of p53 protein was measured in Saos2 cells by cotransfection of a p21-Luc reporter plasmid and p53 together with
Mdm2, Pirh2, Pirh2 	RING, or the empty expression vector pcDNA3.1 as control. Error bars indicate SEM (n  3).
(B) MCF-7 clones stably expressing Pirh2 (PIRH2-1), Pirh2 	RING (	RING-7), Mdm2 (Mdm2), or pcDNA3.1 were transiently transfected with
the p21-Luc reporter plasmid and luciferase activity was measured. Error bars indicate SEM (n  4).
(C) The growth suppressing activity of p53 was measured in H1299 cells by cotransfection of a CD20 expression construct with pcDNA3-p53
(5 g) and pcDNA3-Pirh2 (10 g) or Pirh2 variants as indicated. The number of surviving CD20-positve cells was measured by flow cytometry
48 hr after transfection. Error bars indicate SEM (n  3).
(D) BJT cells were exposed to hPirh2 antisense (AS) and control (C) oligonucleotides for 48 hr and subjected to cell cycle analysis by flow
cytometry. The percentage of cells in G1, S, and G2/M was 67.3, 26.9, and 6.4 for the cells treated with control oligonucleotide, and 74.2,
17.0, and 8.8 for the cells treated with the antisense oligonucleotide. The results represent the average of triplicate experiments.
not shown). These mutants were unable to rescue cells exhibited an increase in the proportion of cells in G1
and a decrease in the proportion of cells in S phase.from p53-mediated cell death (Figure 7C). These data
suggest that the E3 ligase of activity of Pirh2 is required This was reflected by an increase in the G1/S ratio from
2.5 to 4.4 and is consistent with arrest in the G1 phaseto block the growth suppressor function of p53.
of the cell cycle (Figure 7D). Antisense inhibition of Pirh2
expression resulted in elevated levels of p53 proteinDisruption of Pirh2 Potentiates p53-Dependent
Cell Cycle Arrest in BJT cells (Figure 5B). Taken together, these data
demonstrate that Pirh2 is involved in the regulation ofGiven that overexpressed Pirh2 reduces the amount of
endogenous p53 protein and that antisense-mediated p53-mediated transcriptional activation, p53-medi-
ated growth suppression, and p53-mediated checkpointdisruption of Pirh2 increases the amount of endogenous
p53 protein (Figure 5), we wished to determine if Pirh2 control.
inhibition could potentiate the ability of endogenous p53
to arrest BJT fibroblasts in the G1 phase of the cell cycle. Discussion
BJT cells were exposed to control or Pirh2 antisense
oligonucleotide and subjected to cell cycle analysis by We propose that Pirh2 functions as a negative regulator
of p53 and that it participates in an autoregulatory feed-propidium iodide staining and flow cytometry. Cells ex-
posed to the control antisense oligonucleotide exhibited back loop with p53. In contrast with other p53 respon-
sive genes, forced overexpression of Pirh2 in variousa normal cell cycle profile (Figure 7D) and unchanged
levels of Pirh2 and p53 protein (Figure 5B). In contrast, recipient cells did not result in cell cycle arrest or in the
induction of apoptosis. This study raises the possibilityBJT cells exposed to the Pirh2 antisense oligonucleotide
(H) GST-Pirh2 was evaluated for its capacity to ubiquitinate purified His-p53. After the in vitro ubiquitination reaction, the samples were
analyzed by SDS-PAGE and immunoblotting with a His antibody to reveal ubiquitinated products (top image) or with an antibody directed to
p53 (Ab-7) to reveal ubiquitinated p53 species.
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that Pirh2 overexpression in cancer cells may provide these different forms of p53 are negatively regulated
through distinct mechanisms.yet another mechanism to inactivate wild-type p53.
Our studies indicate that the RING-H2 domain of Pirh2 Pirh2 binds to the central core domain of p53 (residues
82–292) and Mdm2 binds to the N-terminal 52 aminois necessary for degradation of p53 and to impair the
growth suppressing activity of p53. In contrast, the acid residues of the p53 protein (Chen et al., 1993).
Whether or not both proteins can bind p53 simultane-RING-H2 domain of Pirh2 is not required for binding to
p53 or to repress the transactivation function of p53. ously is not known. Recently, Gu et al. (2000) identified
a region of p53 consisting of amino acids 92–112 thatThese data suggest that Pirh2-mediated degradation of
p53 is required to inhibit its growth suppressing activity is required for Mdm2-mediated degradation, and they
proposed the existence of a protein that functions withbut not to inhibit its transactivation function. If this inter-
pretation is correct, it implies that p53-mediated growth Mdm2 to target p53 for degradation. At least in vitro,
Pirh2 and Mdm2 are each capable of promoting ubiquiti-suppression involves transactivation-independent func-
tions of p53. nation of p53. Moreover, ectopically expressed Pirh2
promotes ubiquitination in Mdm2 null cells. This doesAn autoregulatory feedback loop involving p53 and
Mdm2 is well established (Barak et al., 1993; Wu et al., not exclude the possibility that the two proteins may
function cooperatively under physiological conditions.1993). Like Mdm2, the Pirh2 gene is transcriptionally
regulated by p53. In addition, both genes encode RING Based on the observation that Mdm2-p53 complexes
and JNK-p53 complexes are present in different phasesdomain-containing proteins that are capable of physi-
cally interacting with p53 and inhibiting the transcrip- of the cell cycle, Fuchs et al. (1998) suggested that
Mdm2 and JNK regulate different functions of p53 duringtional activity of p53. Moreover, Pirh2, like Mdm2, has
ubiquitin-protein ligase activity and can target p53 for normal cell growth. It will be of interest to determine
if the association between p53 and Pirh2 is cell cycleubiquitination and degradation. In the present work, we
have observed that Pirh2 functions independently of dependent, and whether the association and subcellular
localization of these two proteins is influenced by cellu-Mdm2. The striking level of functional similarity between
Pirh2 and Mdm2 raises important questions about re- lar stress or DNA damage.
We have observed substantial heterogeneity in thedundancy and the physiological significance of the mul-
tiple pathways that exert negative control over p53. In induction of Pirh2 transcripts following DNA damage
in different cell lines. The p53-mediated transcriptionaladdition to Mdm2 and Pirh2, three other mechanisms
have been reported to regulate p53 protein levels response to DNA damage is extremely complex. p53-
regulated gene expression patterns differ not only inthrough ubiquitination: the HPV E6 protein targets p53
for ubiquitin-mediated degradation dependent on the different cell types but also in response to different in-
duction signals. There is heterogeneity in kinetics (tim-cellular E6-AP ubiquitin ligase (Scheffner et al., 1993);
the adenovirus E1B55K and E4orf6 proteins function ing, extent) of gene induction as well as on p53 depen-
dency of gene induction. This heterogeneity is seen eventogether to promote p53 ubiquitination and degradation
through a Cullin-containing E3 ubiquitin ligase complex in related cell lines derived from the same lineage (Yu
et al., 1999; Zhao et al., 2000). The complexity of the(Querido et al., 2001); and JNK appears to target p53
for ubiquitin-mediated degradation through an Mdm2- p53 response may reflect the distinct pathways through
which p53 can be activated in response to various stim-independent mechanism (Adler et al., 1997; Fuchs et
al., 1998). Negative control of p53 also occurs at the uli (Appella and Anderson, 2001). It could also reflect
differences in the affinity of various promoters for p53,functional level though the action of Mdm4 (Shvarts et
al., 1996; Jackson and Berberich, 2000), hSIRT1 (Vaziri such that some are responsive only to high levels of p53
or to certain modified forms of p53 (Resnick-Silvermanet al., 2001; Luo et al., 2001) and the HDAC1 complex
(Luo et al., 2000). et al., 1998). A transcription factor, like p53, will have
many targets, and many of these will be codependentThe complexity of the regulatory pathways that target
p53 is illustrated by the fact that mice deficient for Mdm2 on other transcription and regulatory factors that may
or may not be co-expressed with p53.or Mdm4 die early in development. The embryonic lethal-
ity of Mdm2/ and Mdm4/ mice is completely rescued An important question raised by our results is whether
Pirh2 targets other substrates in addition to p53. Weby loss of p53. Hence, Mdm4 and Mdm2 are unable to
substitute for one another, and this suggests that the believe this is likely for a number of reasons. First, ec-
topic Pirh2 expression in p53 null Saos2 cells resulted intwo proteins regulate p53 by nonoverlapping pathways
(Parant et al., 2001). Pirh2, if present during the very ubiquitination of cellular substrates (Figure 5A). Second,
Pirh2 is highly conserved with homologs in yeast, whichearly stages of mouse development, must also not be
able to compensate for loss of Mdm2 or Mdm4. It will do not have p53-like genes. Drosophila p53 protein is
highly divergent from the mammalian p53 isotypes andbe informative to evaluate the expression patterns of
Pirh2, Mdm2, and Mdm4 in the developing embryo to may be more closely related to the p53 homolog, p63
(Yang et al., 2002). The presence of Pirh2 homologs indetermine if these genes are expressed in similar or
different tissues. The possibility that p53 is targeted for lower organisms raises the possibility that Pirh2 may
also target the p53 homologs, p63 and p73. In prelimi-ubiquitination by different pathways, depending on cell
lineage or stage of differentiation, needs to be investi- nary experiments, we have observed binding between
mammalian p73 and Pirh2 (data not shown). Third, en-gated. Furthermore, the fact that p53 assembles as a
tetramer, that it can be covalently modified in response dogenous Pirh2 is expressed in p53 null cells and so its
dependency on p53 is not absolute. Lastly, individualto various stress signals, and that it associates with
various cellular and viral proteins, indicates that different E3s often control the ubiquitination of multiple sub-
strates (Koepp et al., 1999) and so it is not unreasonableforms of p53 co-exist within a cell. It is possible that
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Northern Blot Analysisto think that Pirh2 may target other proteins. Recently,
Total RNA was isolated using the TRIzol reagent (Invitrogen) ac-a protein identical to Pirh2 was shown to bind to the
cording to the manufacturer’s instructions. Each RNA sample (10g)human androgen receptor (Beitel et al., 2002).
was run on a denaturing agarose gel and transferred to a positively
charged nylon membrane. Hybridization of radioactive probes was
Experimental Procedures done using standard conditions. The filters were exposed to X-ray
film and the RNA was visualized by autoradiography. RNA levels
cDNA Cloning were determined with a PhosphorImager using ImageQuant soft-
RNAimage kits (GenHunter) were used for differential display ac- ware (Molecular Dynamics).
cording to manufacturer’s protocol. Full-length cDNA was obtained
by 5-RACE PCR. Sequence analyses and alignments were carried Luciferase Assay
out using the NCBI database and SeqWeb on the GCG Wisconsin pGL3-E1bTATA contains a minimal promoter consisting of a TATA
Package Version 10. box downstream of one copy of the p53 binding site from the 5
end of the p21WAF promoter and is referred to as p21-Luc (Resnick-
Cell Culture and DNA Transfection Silverman et al., 1998). We replaced the p21WAF1-derived sequence
All cells were maintained in 
-minimal essential medium supple- present in p21-Luc with the p53 binding sequence from mouse Pirh2
mented with 10% fetal bovine serum. BJT cells were derived from or with an unrelated sequence of the same length to give rise to
normal human BJ fibroblasts that were immortalized by ectopic Pirh2-Luc and C-Luc, respectively. Expression vectors carrying ei-
expression of the telomerase enzyme. BJT/DD cells express the ther wild-type or mutant p53 (5 g) were cotransfected with the
C-terminal oligomerization domain of p53 (Vaziri et al., 2001). BaF3/ luciferase reporter construct (5 g) into p53-negative Saos2 cells
DD cells were established by retroviral infection of BaF3 cells with by calcium phosphate precipitation. A-galactosidase reporter con-
a pBabe-p53DDneo. For the derivation of stable MCF-7 cell lines, struct, pCMV--gal (Promega), was included in all the transfection
cells were transfected using lipofectin and selected in 500 g/ml of mixes. Luciferase activity was measured 2 days posttransfection on
G418. For transient assays, plasmids or antisense oligonucleotides samples containing equivalent amounts of protein using an LB9507
were transfected using calcium phosphate. Phosphorothioate-mod- luminometer and the luciferase assay reagent (Promega); values
ified, HPLC-purified oligodeoxynucleotides were obtained from In- were normalized to -galactosidase activity.
vitrogen. hPirh2 AS: CCGGGCCGTCGCCGCCAT; scrambled control
oligonucleotide: TGCCCTGCCGCGACGGCC. The hPirh2 AS oligo- Recombinant Protein Preparation
nucleotide targets the translation initiation codon in human Pirh2 (See Supplemental Data available at http://www.cell.com/cgi/
mRNA. content/full/112/6/779/DC1).
Mammalian Expression Vectors GST Pull-down Assay
pcDNA3.1 served as the backbone mammalian expression vector (See Supplemental Data available at above website.)
for p53 and Pirh2. pCMV-Bam-Mdm2 (Oliner et al., 1993) was used
for Mdm2 expression. The mammalian expression vector of His- Metabolic Labeling and Immunoprecipitation Analysis
Pirh2 was pTris-Ex-1 (Novagene). The RING domain of human Pirh2 Saos2 cells were transfected with pcDNA3-Pirh2 alone or in combi-
was removed from pcDNA3.1-Pirh2 by PCR amplification of appro- nation with pcDNA3-p53. After 24 hr, the transfected cells were
priate fragments and ligation. The Pirh2 mutants C164A and H169A washed with methionine- and cysteine-free medium and starved for
were generated by site-directed mutagenesis (Quick Change, Stra- methionine and cysteine for 1 hr. Cells were metabolically labeled
tagene). with 200 Ci of 35S-methionine/cysteine for 2 hr. Subsequently, cells
were collected by centrifugation, washed with PBS, lysed in 50 mM
Antibodies Tris-HCl [pH 8.0], 5 mM EDTA, 150 mM NaCl, and 0.5% NP-40,
p53 detection was carried out using PAb421 (Harlow et al., 1981), and immunoprecipitated with antibodies against Pirh2. The immune
PAb1801 (Banks et al., 1986), FL-393 (Santa Cruz Biotechnology) complexes were collected with protein A-agarose beads, washed
or Ab-7 (Oncogene Research Products). Monoclonal antibodies four times with buffer containing 5% sucrose, 5.0 mM Tris-HCl [pH
against the HA-epitope (12CA5, Roche), the His-epitope (Novagen), 7.4], 5 mM EDTA, 0.5 M NaCl, and 1% NP-40. The immunoprecipi-
and antibodies to -actin (Sigma) and Mdm2 (Ab-1, Oncogene Re- tates were analyzed by SDS-PAGE followed by autoradiography. For
search Products; smp14, Santa Cruz) were used for immunoprecipi- pulse-chase analysis, the p53/ Mdm2/ double-null cells were
tation and immunoblotting. Antiserum against Pirh2 was raised in transfected with p53 and Pirh2 expression vectors and labeled 24
rabbits against the purified His-Pirh2 fusion protein and affinity- hr later with [35S]methionine/cysteine as described above. The cells
purified on GST-Pirh2 Sepharose beads or by adsorption to, and were washed and chased in non-radioactive medium for various
elution from, Pirh2 protein immobilized on nitrocellulose filters after periods of time. Lysates containing the same amount of trichloro-
SDS-PAGE. acetic acid-insoluble radioactivity were immunoprecipitated with
polyclonal antibodies to p53 (FL-393) and analyzed by gel electro-
phoresis and autoradiography.Cell Viability Assay
H1299 cells were transfected using the calcium phosphate method
with 3 g CMV-CD20 in the presence or absence of pcDNA3-p53 Chromatin Immunoprecipitation
(5 g) and pcDNA3-hPirh2 or its variants (10 g). Forty-eight hours (See Supplemental Data available at above website.)
after transfection, cells were stained with a FITC-conjugated anti-
CD20 antibody (Pharmingen) in the presence of 1% BSA for 30 In Vitro Ubiquitination Assay
min at 4C and the number of surviving CD20-positve cells was Ubiquitination assays were carried out by adding GST-Pirh2
determined by flow cytometry. A decrease in the number of CD20- (0.5–1 g), rabbit E1 (40 ng, Calbiochem), UbcH5b (100 ng, Calbio-
positive cells provided a measure of p53-mediated cell death. chem), His-tagged ubiquitin (2g, Sigma) and 2l of BL-21 bacterial
lysate in ubiquitination buffer (50 mM Tris-HCl [pH 7.4], 2 mM ATP,
5 mM MgCl, 2 mM DTT, 30 mM creatine phosphate, and 0.05 mg/Cell Cycle Analysis
BJT cells were washed once with PBS and incubated on ice in 0.1% ml creatine phosphokinase) to a final volume of 30 l. The reactions
were incubated at 30C for 1.5–2 hr. The reactions were stoppedsodium citrate, 0.2% NP-40, 200 g/ml RNase A, and 50 g/ml
propidium iodide to release nuclei and stain the DNA. Cell cycle with 2  SDS loading buffer, heated to 95C for 6 min, and the
proteins were separated on a 10% SDS-PAGE. Ubiquitinated pro-distribution was examined by flow cytometry using a FACScan flow
cytometer (Becton Dickinson) and CellQuest software (Becton Dick- teins were visualized by immunoblotting using a His antibody.
For p53 ubiquitination assays, 35S-labeled p53 protein was synthe-inson). The relative proportion of cells in each phase of the cell
cycle was determined using the automated ModFit program (Verity sized by in vitro transcription and translation using the TNT T7
coupled reticulocyte lysate system (Promega). 2  104 cpm of inSoftware House Incorporated).
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vitro translated p53 were added to GST-Pirh2 (1–5 g) and mixed Gu, J., Chen, D., Rosenblum, J., Rubin, R.M., and Yuan, Z. (2000).
Identification of a sequence element from p53 that signals for Mdm2-on ice for at least 1 hr to form GST-Pirh2:p53 complexes. These
complexes were then mixed with ubiquitination buffer and rabbit targeted degradation. Mol. Cell. Biol. 20, 1243–1253.
E1 (200 ng), UbcH5b (50 ng), and Ub (5 g). The reactions were Harlow, E., Crawford, L.V., Pim, D.C., and Williamson, N.M. (1981).
incubated at 30C for 1.5–2 hr, stopped with 2 SDS loading buffer, Monoclonal antibodies specific for simian virus 40 tumor antigens.
resolved on 10% SDS-PAGE and analyzed by autoradiography. J. Virol. 39, 861–869.
Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes
In Vivo Ubiquitination Assay the rapid degradation of p53. Nature 387, 296–299.
Saos2 cells were transfected with expression plasmids encoding
Honda, R., and Yasuda, H. (2000). Activity of MDM2, a ubiquitinp53, Pirh2, Mdm2, and HA-tagged ubiquitin either alone or in combi-
ligase, toward p53 or itself is dependent on the RING finger domainnation. Cells were collected 24 hr after transfection, lysed in modified
of the ligase. Oncogene 19, 1473–1476.RIPA buffer (2 mM Tris-HCl [pH 7.5], 5 mM EDTA, 150 mM NaCl,
Honda, R., Tanaka, H., and Yasuda, Y. (1997). Oncoprotein MDM21% NP-40, 1% deoxycholate, 0.025% SDS, and 1 mM PMSF), and
is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420,analyzed by immunoblotting or by IP/immunoblotting. For immuno-
25–27.precipitation, the lysates were sonicated and clarified by centrifuga-
tion at 4C for 15 min to remove cellular debris. Lysates (1 mg) Jackson, M.W., and Berberich, S.J. (2000). MdmX protects p53 from
were incubated with antibody against p53 (PAb1801 or FL-393). The Mdm2-mediated degradation. Mol. Cell. Biol. 20, 1001–1007.
immunoprecipitates were collected with protein A-agarose beads,
Johnson, P., Chung, S., and Benchimol, S. (1993). Growth suppres-
washed with RIPA buffer, separated on 10% SDS-PAGE, and trans-
sion of friend virus-transformed erythroleukemia cells by p53 protein
ferred to PVDF membranes. The membranes were immunoblotted
is accompanied by hemoglobin production and is sensitive to eryth-
with polyclonal antibodies against p53 (Ab-7) or HA.
ropoietin. Mol. Cell. Biol. 13, 1456–1463.
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